Adicon Holdings Limited

SZSC:9860 Stock Report

Market Cap: HK$4.6b

Adicon Holdings Valuation

Is 9860 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 9860 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 9860 (HK$6.4) is trading above our estimate of fair value (HK$0.33)

Significantly Below Fair Value: 9860 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 9860?

Key metric: As 9860 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 9860. This is calculated by dividing 9860's market cap by their current earnings.
What is 9860's PE Ratio?
PE Ratio19.2x
EarningsCN¥224.66m
Market CapCN¥4.32b

Price to Earnings Ratio vs Peers

How does 9860's PE Ratio compare to its peers?

The above table shows the PE ratio for 9860 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average39.3x
6606 New Horizon Health
52.8x60.4%HK$6.3b
1951 Jinxin Fertility Group
23.9x19.4%HK$8.0b
2273 Gushengtang Holdings
28.5x32.8%HK$8.2b
6667 Mega Genomics
51.8xn/aHK$1.8b
9860 Adicon Holdings
19.2x20.2%HK$4.6b

Price-To-Earnings vs Peers: 9860 is good value based on its Price-To-Earnings Ratio (19.2x) compared to the peer average (39.3x).

Price to Earnings Ratio vs Industry

How does 9860's PE Ratio compare vs other companies in the HK Healthcare Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
574 Pa Shun International Holdings
1.9xn/aUS$8.72m
No more companies available in this PE range
9860 19.2xIndustry Avg. 13.0xNo. of Companies11PE01224364860+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 9860 is expensive based on its Price-To-Earnings Ratio (19.2x) compared to the Hong Kong Healthcare industry average (13x).

Price to Earnings Ratio vs Fair Ratio

What is 9860's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

9860 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio19.2x
Fair PE Ratio15.9x

Price-To-Earnings vs Fair Ratio: 9860 is expensive based on its Price-To-Earnings Ratio (19.2x) compared to the estimated Fair Price-To-Earnings Ratio (15.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 9860 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentHK$6.40
HK$10.52
+64.4%
14.7%HK$12.43HK$7.19n/a7
Nov ’25HK$6.68
HK$10.88
+62.8%
10.7%HK$12.61HK$8.68n/a7
Oct ’25HK$9.20
HK$11.22
+21.9%
9.7%HK$12.69HK$8.80n/a7
Sep ’25HK$9.00
HK$14.89
+65.5%
7.9%HK$16.14HK$12.81n/a6
Aug ’25HK$9.58
HK$14.68
+53.3%
7.9%HK$15.88HK$12.60n/a6
Jul ’25HK$10.20
HK$14.87
+45.8%
5.7%HK$15.88HK$13.76n/a6
Jun ’25HK$8.18
HK$15.50
+89.5%
10.1%HK$18.45HK$13.80n/a6
May ’25HK$11.68
HK$15.52
+32.9%
10.4%HK$18.51HK$13.71n/a6
Apr ’25HK$12.00
HK$15.59
+30.0%
10.2%HK$18.55HK$13.74n/a6
Mar ’25HK$12.18
HK$16.54
+35.8%
13.1%HK$20.21HK$13.81n/a6
Feb ’25HK$9.49
HK$16.63
+75.2%
14.2%HK$20.19HK$13.79n/a5
Jan ’25HK$13.04
HK$17.56
+34.6%
9.2%HK$20.17HK$15.78n/a5
Dec ’24HK$10.10
HK$17.56
+73.8%
9.2%HK$20.17HK$15.78n/a5
Nov ’24HK$11.36
HK$17.15
+51.0%
9.5%HK$19.70HK$15.28HK$6.685
Oct ’24HK$16.00
HK$17.24
+7.8%
9.7%HK$19.85HK$15.40HK$9.205
Sep ’24n/a
HK$17.24
0%
9.7%HK$19.85HK$15.40HK$9.005

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Hygeia Healthcare Holdings

HK$10.2b

Offers oncology healthcare services in the People's Republic of China.

6078

HK$16.40

7D

-6.6%

1Y

-66.9%

Hygeia Healthcare Holdings

HK$10.2b

Offers oncology healthcare services in the People's Republic of China.

6078

HK$16.40

7D

-6.6%

1Y

-66.9%

Sinopharm Group

HK$62.6b

Engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China.

1099

HK$20.60

7D

-0.2%

1Y

6.1%